U.S. panel backs AstraZeneca Plc's FluMist for kids
Daily Record, The (Baltimore), Oct 25, 2007
AstraZeneca Plc's FluMist, the nasal spray influenza vaccine, was recommended for children 2 years to 4 years old by a U.S. panel of advisers. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted Tuesday to widen its recommendation for FluMist, which had been recommended for healthy people ages 5 to 49.
Children with asthma, wheezing and other breathing disorders were counseled against using the spray vaccine. British drug maker AstraZeneca inherited FluMist when it acquired the drug's developer, Gaithersburg-based MedImmune Inc., in June.
Copyright 2007 Dolan Media Newswires
Provided by ProQuest Information and Learning Company. All rights Reserved.
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- Design a commission plan that drives sales - Sales Commissions
Most Popular Business Publications
Content provided in partnership with
